The GORASP2 Knockout A-549 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population targeting the GORASP2 gene in the human A-549 lung epithelial cell line. This polyclonal population offers a heterogeneous mixture of gene-disrupted cells, enabling the study of GORASP2 function without the limitations of single-cell clonal selection. The CRISPR/Cas9-mediated gene disruption creates a loss-of-function model that is suitable for investigating the roles of GORASP2 in Golgi biology and related cellular processes. These polyclonal knockout cells are ideal for applications requiring a representative population-level readout, such as secretome analysis and high-throughput screening.
The host cell line, A-549, is a well-characterized human lung adenocarcinoma epithelial cell line derived from a 58-year-old Caucasian male. These cells are widely used as a model system for lung adenocarcinoma, particularly in studies of cancer cell biology, metastasis, and drug responses. A-549 cells retain epithelial characteristics and express markers such as E-cadherin, making them relevant for investigating epithelial-mesenchymal transition and tumor invasion. The cell line’s robust growth and compatibility with various assays provide a reliable platform for genetic manipulation and functional genomics studies.
GORASP2 (also known as GRASP55) encodes a Golgi stacking protein critical for the maintenance of Golgi ribbon architecture. It functions in concert with GORASP1 (GRASP65) and the Golgin protein GOLGA2 (GM130) to tether adjacent Golgi cisternae, facilitating proper glycosylation and protein sorting. GORASP2 is regulated by mitotic kinases such as CDK1 and PLK1, which phosphorylate it during cell division to promote Golgi disassembly. Its activity is also modulated by the mTORC1 signaling pathway, linking nutrient sensing to Golgi organization and autophagy. Downstream, GORASP2 influences the secretion of glycoproteins and interacts with autophagy-related factors, including MAP1LC3B and SQSTM1/p62, to regulate autophagosome-lysosome fusion. Disruption of GORASP2 alters Golgi structure, potentially affecting the trafficking and modification of proteins involved in cell adhesion and signaling.
In the A-549 lung adenocarcinoma cell line, knockout of GORASP2 provides a powerful model to dissect how Golgi dysfunction impacts cancer cell behavior. Aberrant Golgi structure in GORASP2-deficient cells can lead to altered glycosylation patterns of cell surface receptors and secreted factors, which may influence cell migration, invasion, and metastatic potential. Given A-549 cells’ origin from metastatic lung adenocarcinoma, this model is particularly relevant for studying the Golgi’s role in cancer progression. Additionally, impaired autophagy due to disrupted GORASP2-mTORC1 crosstalk may sensitize the cells to stress or therapeutic agents, offering insights into novel treatment strategies.
Researchers can employ this polyclonal knockout cell population in a variety of advanced assays, including immunofluorescence staining of Golgi markers like GOLGA2 to assess morphological changes, western blotting to detect altered glycosylation of proteins, and migration/invasion assays using Boyden chambers to quantify metastatic potential. Secretion assays can measure changes in the secretome, while autophagy flux analysis using LC3B-II turnover or p62 degradation assays can probe the GORASP2-autophagy link. This model also supports high-throughput screening for compounds that modulate Golgi-related functions or restore wild-type phenotypes. For further details and technical support, please contact Ascent Research.
